샘플 요청 목록

 카트 문의
시장보고서
상품코드
1788375

세계의 투렛 증후군 치료 시장

Tourette Syndrome Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 186 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 투렛 증후군 치료 시장은 2030년까지 31억 달러에 도달

2024년에 23억 달러로 추정되는 세계의 투렛 증후군 치료 시장은 분석 기간인 2024-2030년에 CAGR 5.1%로 성장하며, 2030년에는 31억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 항정신병약은 CAGR 4.1%를 기록하며, 분석 기간 종료시에는 20억 달러에 달할 것으로 예측됩니다. 비항정신병약 부문의 성장률은 분석 기간 중 CAGR 7.0%로 추정됩니다.

미국 시장은 추정 6억 2,600만 달러, 중국은 CAGR 7.9%로 성장 예측

미국의 투렛 증후군 치료 시장은 2024년에 6억 2,600만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 7.9%로, 2030년까지 6억 990만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.5%와 5.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.3%로 성장할 것으로 예측됩니다.

투렛 증후군 치료 시장의 동향과 촉진요인 정리

뚜렛 증후군 치료는 맞춤형 의료와 신경조절로 어떻게 발전하고 있는가?

뚜렛증후군(TS)은 반복적이고 불수의적인 틱과 발성을 특징으로 하는 신경질환으로, 주로 어린 시절에 발병하는 경우가 많습니다. 정확한 원인은 밝혀지지 않았지만, 연구에 따르면 유전적, 신경학적, 환경적 요인이 복합적으로 관여하는 것으로 알려져 있습니다. 역사적으로 치료 옵션은 행동치료와 도파민 길항제, α-adrenergic agonist와 같은 약리학적 중재에 국한되어 왔습니다. 하지만 맞춤형 의료, 신경조절기술, 유전자치료가 강조되면서 치료법은 크게 변화하고 있습니다. 뇌심부자극요법(DBS)과 경두개자기자극요법(TMS)은 기존 약물 치료의 부작용 없이 증상 조절을 개선하는 유망 비침습적 솔루션으로 부상하고 있습니다. 그러나 진단 지연, 증상 중증도 편차, 치료 접근성 제한 등의 문제는 여전히 남아있습니다. 신경정신의학 연구가 진행됨에 따라 표적치료와 디지털 치료의 기술 혁신이 뚜렛 증후군 치료의 미래를 어떻게 재정의할 수 있는가?

투렛 증후군 치료를 발전시키고 있는 기술 혁신은 어떤 것이 있는가?

최근 TS 치료의 획기적인 발전은 정밀한 신경조절, AI 기반 진단 툴, 약물유전체학에 초점을 맞추었습니다. 원래 파킨슨병을 위해 개발된 DBS는 현재 TS를 위해 연구되고 있으며, 비정상적인 신경회로를 조절하는 데 도움을 주고 있습니다. AI 기반 인지행동치료(CBT) 앱은 원격으로 틱을 관리할 수 있으며, 치료를 더욱 친숙하게 만들고 있습니다. 유전학적 연구를 통해 TS의 잠재적인 바이오마커가 밝혀지고 있으며, 환자 개개인에 맞는 표적 치료의 길이 열리고 있습니다. 또한 실시간 바이오피드백 메커니즘을 갖춘 웨어러블 기기가 디지털 치료제로 부상하고 있으며, 뉴로피드백 및 습관 반전 훈련을 통해 틱 장애 관리를 돕고 있습니다.

투렛 증후군 치료 수요가 증가하는 이유는 무엇인가?

신경 발달 장애의 유병률 증가, TS에 대한 인식 증가, 비침습적 신경조절의 발전은 혁신적인 치료법에 대한 수요를 촉진하고 있습니다. 부모와 보호자들은 부작용에 대한 우려로 약물 치료 이외의 대체요법을 원하고 있습니다. 또한 원격의료 및 디지털 치료법의 채택이 증가함에 따라 행동 중재에 대한 접근성이 확대되어 시장 성장을 더욱 촉진하고 있습니다.

투렛 증후군 치료제 시장의 성장을 가속하는 요인은 무엇인가?

신경 자극 치료의 발전, 유전학 및 신경생물학적 메커니즘에 대한 연구 증가, 비약물 요법에 대한 수요 증가, 디지털 헬스 솔루션의 확대 등으로 시장이 확대되고 있습니다. 투렛 증후군에 대한 이해가 진전됨에 따라 향후 치료는 개별화된 기술 기반 개입에 초점을 맞출 것이며, 이는 환자의 결과와 삶의 질을 향상시킬 가능성이 높습니다.

부문

치료 유형(항정신병약, 비항정신병약)

조사 대상 기업의 예

  • AbbVie Inc.
  • Abide Therapeutics
  • Acorda Therapeutics
  • Anika Therapeutics Inc.
  • Apotex Inc.
  • Arbor Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Catalyst Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Emalex Biosciences, Inc.
  • F. Hoffmann-La Roche AG
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Kyowa Kirin Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.19

Global Tourette Syndrome Treatment Market to Reach US$3.1 Billion by 2030

The global market for Tourette Syndrome Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.1 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Antipsychotics, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Non-Antipsychotics segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$626.0 Million While China is Forecast to Grow at 7.9% CAGR

The Tourette Syndrome Treatment market in the U.S. is estimated at US$626.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$609.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Tourette Syndrome Treatment Market Trends & Drivers Summarized

How Is Tourette Syndrome Treatment Advancing with Personalized Medicine and Neuromodulation?

Tourette Syndrome (TS) is a neurological disorder characterized by repetitive, involuntary tics and vocalizations, often appearing in childhood. While the exact cause remains unclear, research indicates a combination of genetic, neurological, and environmental factors. Historically, treatment options have been limited to behavioral therapy and pharmacological interventions, such as dopamine antagonists and alpha-adrenergic agonists. However, the growing emphasis on personalized medicine, neuromodulation techniques, and gene therapy is transforming the treatment landscape. Deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS) are emerging as promising non-invasive solutions for severe cases, offering improved symptom control without the side effects associated with traditional medications. However, challenges such as delayed diagnosis, variability in symptom severity, and limited treatment accessibility persist. As neuropsychiatric research advances, how will innovations in targeted therapies and digital therapeutics redefine the future of Tourette Syndrome treatment?

What Technological Innovations Are Advancing Tourette Syndrome Treatment?

Recent breakthroughs in TS treatment focus on precision neuromodulation, AI-driven diagnostic tools, and pharmacogenomics. DBS, originally developed for Parkinson’s disease, is now being explored for TS, helping to regulate abnormal neural circuits. AI-based cognitive behavioral therapy (CBT) apps are enabling remote tic management, making treatment more accessible. Genetic research is uncovering potential biomarkers for TS, paving the way for targeted therapies tailored to individual patients. Additionally, wearable devices with real-time biofeedback mechanisms are emerging as digital therapeutics, helping individuals manage tics through neurofeedback and habit-reversal training.

Why Is the Demand for Tourette Syndrome Treatment Increasing?

The increasing prevalence of neurodevelopmental disorders, growing awareness of TS, and advancements in non-invasive neuromodulation are driving demand for innovative treatments. Parents and caregivers are seeking alternative therapies beyond medication due to concerns over side effects. Additionally, the rising adoption of telemedicine and digital therapeutics is expanding access to behavioral interventions, further fueling market growth.

What Factors Are Driving the Growth of the Tourette Syndrome Treatment Market?

The market is expanding due to advancements in neurostimulation therapies, increasing research into genetic and neurobiological mechanisms, growing demand for non-pharmacological treatments, and expanding digital health solutions. As the understanding of Tourette Syndrome improves, future treatments will likely focus on personalized and technology-driven interventions, enhancing patient outcomes and quality of life.

SCOPE OF STUDY:

The report analyzes the Tourette Syndrome Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Antipsychotics, Non-Antipsychotics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Abide Therapeutics
  • Acorda Therapeutics
  • Anika Therapeutics Inc.
  • Apotex Inc.
  • Arbor Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Catalyst Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Emalex Biosciences, Inc.
  • F. Hoffmann-La Roche AG
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Kyowa Kirin Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Tourette Syndrome Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Diagnosis Rates and Awareness Campaigns Drive Demand for Therapeutic Options
    • Expansion of Behavioral Therapy Access Enhances Non-Pharmacologic Treatment Demand
    • Clinical Development of Dopamine Modulators and VMAT2 Inhibitors Advances Drug Pipeline
    • Rise in Pediatric Neuropsychiatry Services Strengthens Early Intervention Initiatives
    • Growing Research Into Comorbidity Management (ADHD, OCD) Expands Treatment Scope
    • Use of Digital CBT Tools and Virtual Consults Supports Decentralized Behavioral Therapies
    • Development of Long-Acting Injectable Formulations Improves Adherence and Quality of Life
    • Clinical Trials Targeting Genetic and Neurobiological Mechanisms Enhance Innovation
    • Regulatory Fast Track and Orphan Drug Status Incentivize R&D Investment
    • Integration of Multidisciplinary Care Models Improves Treatment Coordination
    • Advocacy Group Engagement and Support Networks Improve Patient Retention
    • Emerging Interest in Neuromodulation and DBS for Refractory Cases Expands Research Frontiers
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tourette Syndrome Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tourette Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • JAPAN
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • CHINA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • EUROPE
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Tourette Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • FRANCE
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • GERMANY
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Tourette Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • INDIA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Tourette Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Tourette Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • AFRICA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제